Li S, Zhou Z, Long H, Yin J, Wang H, Zhao J
Transl Gastroenterol Hepatol. 2025; 10:17.
PMID: 39944577
PMC: 11811550.
DOI: 10.21037/tgh-24-91.
Fu Y, Li W, Cai H, Jiao Y
World J Gastrointest Surg. 2024; 16(12):3903-3906.
PMID: 39734435
PMC: 11650251.
DOI: 10.4240/wjgs.v16.i12.3903.
Wang D, Zhang L, Yang W, Zhang L, Yu C, Qin J
Adv Sci (Weinh). 2024; 12(6):e2410484.
PMID: 39680010
PMC: 11809372.
DOI: 10.1002/advs.202410484.
Jeong B, Heo S, Lee S, Kim S, Shin Y, Kim K
Eur Radiol. 2024; .
PMID: 39528755
DOI: 10.1007/s00330-024-11173-w.
Marzi L, Mega A, Turri C, Gitto S, Ferro F, Spizzo G
Int J Mol Sci. 2024; 25(21).
PMID: 39519230
PMC: 11547112.
DOI: 10.3390/ijms252111676.
Yttrium-90 radioembolization treatment strategies for management of hepatocellular carcinoma.
Hao K, Paik A, Han L, Makary M
World J Radiol. 2024; 16(10):512-527.
PMID: 39494134
PMC: 11525828.
DOI: 10.4329/wjr.v16.i10.512.
Sorafenib plus memory-like natural killer cell immunochemotherapy boosts treatment response in liver cancer.
Eresen A, Zhang Z, Yu G, Hou Q, Chen Z, Yu Z
BMC Cancer. 2024; 24(1):1215.
PMID: 39350084
PMC: 11443676.
DOI: 10.1186/s12885-024-12718-4.
Frontline evaluation: Atezolizumab-bevacizumab versus lenvatinib for BCLC stage B hepatocellular carcinoma exceeding the up-to-seven criteria.
Kimura M, Nishikawa K, Imamura J, Kimura K
Cancer Med. 2024; 13(18):e70217.
PMID: 39300938
PMC: 11413408.
DOI: 10.1002/cam4.70217.
Development and validation of a nomogram for predicting microvascular invasion and evaluating the efficacy of postoperative adjuvant transarterial chemoembolization.
Tu S, He Y, Shu X, Bao S, Wu Z, Cui L
Heliyon. 2024; 10(17):e36770.
PMID: 39290260
PMC: 11407026.
DOI: 10.1016/j.heliyon.2024.e36770.
The influence of peritumoral parenchyma on local tumor progression of hepatocellular carcinoma after thermal ablation: a retrospective multicenter study.
Ding W, Bi M, Gao Y, Zheng L, Chen J, Liu F
Abdom Radiol (NY). 2024; 50(2):710-719.
PMID: 39207515
DOI: 10.1007/s00261-024-04543-x.
Polyphyllin I exerts anti-hepatocellular carcinoma activity by targeting ZBTB16 to activate the PPARγ/RXRα signaling pathway.
Shan L, Chen Y, An G, Tao X, Qiao C, Chen M
Chin Med. 2024; 19(1):113.
PMID: 39182119
PMC: 11344421.
DOI: 10.1186/s13020-024-00984-0.
Treatment of Hepatocellular Carcinoma with Combined Transarterial Chemoembolization and Systemic Therapy.
Khilwani H, Stettner S, Sonnabend K, Chen Y, Jain S, Gaba R
Semin Intervent Radiol. 2024; 41(3):309-316.
PMID: 39165657
PMC: 11333115.
DOI: 10.1055/s-0044-1787835.
Retrospective analysis of the efficacy and survival associated with cTACE and DEB-TACE in the palliative treatment of hepatocellular carcinoma: experience of a tertiary care hospital in southern Brazil.
Fontana P, Coral G, Horbe A, Jotz R, de Morais B, de Mattos A
Radiol Bras. 2024; 57:e20230105.
PMID: 38993962
PMC: 11235059.
DOI: 10.1590/0100-3984.2023.0105.
Multidisciplinary Care and Multimodal Treatment Approaches for Unresectable Hepatocellular Carcinoma.
Lang D, Agarwal R, Brown S, Borgmann A, Lockney N, Goff L
Adv Oncol. 2024; 4(1):247-262.
PMID: 38882260
PMC: 11178262.
DOI: 10.1016/j.yao.2024.02.002.
Albumin-bilirubin grade as a predictor of survival in hepatocellular carcinoma patients with thrombocytopenia.
Man Z, Gong X, Qu K, Pang Q, Wu B
World J Gastrointest Oncol. 2024; 16(5):1763-1772.
PMID: 38764822
PMC: 11099442.
DOI: 10.4251/wjgo.v16.i5.1763.
Multiple asynchronous recurrence as a predictive factor for refractoriness against locoregional and surgical therapy in patients with intermediate-stage hepatocellular carcinoma.
Kasuga R, Taniki N, Chu P, Tamura M, Tabuchi T, Yamaguchi A
Sci Rep. 2024; 14(1):10896.
PMID: 38740983
PMC: 11091100.
DOI: 10.1038/s41598-024-61611-4.
A history of the treatment of primary liver cancer.
Bruix J
Clin Liver Dis (Hoboken). 2024; 23(1):e0147.
PMID: 38707239
PMC: 11068144.
DOI: 10.1097/CLD.0000000000000147.
The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma.
Liu Q, Wang X, Ji H, Dou Q, Zhang H
Med Oncol. 2024; 41(5):91.
PMID: 38526607
DOI: 10.1007/s12032-024-02309-5.
Development and validation of nomograms to evaluate the survival outcome of HCC patients undergoing selective postoperative adjuvant TACE.
He Y, Qian J, Zhu G, Wu Z, Cui L, Tu S
Radiol Med. 2024; 129(4):653-664.
PMID: 38512609
DOI: 10.1007/s11547-024-01792-0.
Threatment Strategies for Recurrent Hepatocellular Carcinoma Patients: Ablation and its Combination Patterns.
Zhao Y, Bai J, Wang X, Zhang Y, Yan X, Qi J
J Cancer. 2024; 15(8):2193-2205.
PMID: 38495485
PMC: 10937274.
DOI: 10.7150/jca.93885.
